Edgewise Therapeutics (EWTX) announced changes to its executive team. These changes include the addition of Robert Blaustein, joining the ...
Stifel initiated coverage of Edgewise Therapeutics (EWTX) with a Hold rating and $30 price target The firm says that while Edgewise has “very ...
We can readily understand why investors are attracted to unprofitable companies. For example, Edgewise Therapeutics (NASDAQ:EWTX) shareholders have done very well over the last year, with the ...
We can readily understand why investors are attracted to unprofitable companies. For example, Edgewise Therapeutics (NASDAQ:EWTX) shareholders have done very well over the last year, with the share ...